Stock COEP COEPTIS THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Coeptis Therapeutics Holdings, Inc.

Equities

COEP

US19207A1088

Real-time Estimate Cboe BZX
Other stock markets
 12:29:23 27/06/2024 am IST 		5-day change 1st Jan Change
0.285 USD -2.93% Intraday chart for Coeptis Therapeutics Holdings, Inc. -2.84% -63.31%
17/06 Ladenburg Downgrades Coeptis Therapeutics to Neutral From Buy MT
14/06 Coeptis Therapeutics Holdings, Inc. announced that it has received $4.3 million in funding CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Coeptis Therapeutics : CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF COEPTIS THERAPEUTICS HOLDINGS, INC Form 8 K
PU
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
PR
Coeptis Therapeutics Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
AQ
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
PR
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
PR
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene and Cell Therapy 27th Annual Meeting
AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award
AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award
PR
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
AQ
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
PR
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
PR
Coeptis Therapeutics to Present at the Emerging Growth Conference
PR
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
PR
Coeptis Therapeutics Announces $2 Million Private Placement
PR
Coeptis Therapeutics : Private Placement - Form 8-K
PU
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology
PR
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies
PR
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting
PR
Coeptis Therapeutics to Present at the 2023 Cell and Gene Meeting on the Mesa
AQ
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COEP Stock
  4. News Coeptis Therapeutics Holdings, Inc.
  5. Press Releases